All In Biotech

Drug Trial Radar · NCT05834348

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Drug Treatment Patterns and Effects for Metastatic Non-small Cell Lung Cancer Patients In NORway (DELINOR)

Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

5,279

Actual

Start

Jun 23, 2023

Primary completion

Jan 23, 2024

Study completion Jan 23, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Apr 28, 2023

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of the study is to learn about the effectiveness and treatment sequence of lung cancer medicines. This study is performed outside of clinical trials in Norway in patients with metastatic non-small cell lung cancer. Non-small cell lung cancer is a group of lung cancers named for the kinds of cells found in the cancer and how the cells look under a microscope. Metastasis is when the cancer cells spread to other parts of the body. This study includes patient's data from the database who: * Are 18 years of age or older. * Are confirmed to have metastatic non-small cell lung cancer between 01 January 2009 and 31 December 2022. The study is based on data collection from 3 national health registries: * The Cancer Registry of Norway (CRN), * The Norwegian Patient Registry (NPR), * The Norwegian Drug Registry (NDR). Data from these registries will be linked at an individual patient level to create a single, unified dataset. The information collected includes: Diagnosis, cancer stage at diagnosis, date of diagnosis, birth year, type of medicinal treatment, date of treatment start and end, treating hospital, age, gender, etc.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • lorlatinibDrug

    As provided in real world practice

  • crizotinibDrug

    As provided in real world practice

  • brigatinibDrug

    As provided in real world practice

  • ceritinibDrug

    As provided in real world practice

  • alectinibDrug

    As provided in real world practice

  • atezolizumabDrug

    As provided in real world practice

  • bevacizumabDrug

    As provided in real world practice

  • paclitaxelDrug

    As provided in real world practice

  • carboplatinDrug

    As provided in real world practice

  • docetaxelDrug

    As provided in real world practice

  • erlotinibDrug

    As provided in real world practice

  • gefitinibDrug

    As provided in real world practice

  • afatinibDrug

    As provided in real world practice

  • dacomitinibDrug

    As provided in real world practice

  • osimertinibDrug

    As provided in real world practice

  • pembrolizumabDrug

    As provided in real world practice

  • nivolumabDrug

    As provided in real world practice

  • entrectinibDrug

    As provided in real world practice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of Treatment of Anti-cancer DrugsTime frame: From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study
  2. Number of Participants Classified According to Treatments of Anti-cancer DrugsTime frame: From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study
  3. Number of Participants Classified According to Treatment Lines of Anti-cancer DrugsTime frame: From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study
  4. Overall Survival (OS)Time frame: From treatment initiation (1-Jan-2015) to date of death (until 31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pfizer Norway

    Oslo, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.